8-K
filed May 29, 2026, 4:45 PM ET
ticker SYRE
CIK 0001636282
other material
confidence high
sentiment neutral
materiality 0.30
Spyre Therapeutics stockholders approve amended ESPP; director Peter Harwin resigns
Spyre Therapeutics, Inc.
- Stockholders approved amended and restated 2016 ESPP (66.9M for, 45.5K against) at May 27 annual meeting.
- Director Peter Harwin resigned effective May 27, 2026; Board reduced from 8 to 7 directors.
- Elected Class I directors Mark McKenna, Cameron Turtle, and Laurie Stelzer to 2029 term.
- Non-binding advisory vote on executive compensation passed with 62.1M for, 4.8M against.
- Ratification of KPMG as independent auditor for FY2026 passed with 68.4M for, 670 against.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Peter Harwin resigned as Director at Spyre Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
In addition, effective as of May 27, 2026, Peter Harwin resigned from the Board.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Spyre Therapeutics, Inc. shareholders approved Approval of Amended and Restated 2016 Employee Stock Purchase Plan at the 2026-05-27 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
The Company’s stockholders approved the Company's AR ESPP.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Spyre Therapeutics, Inc. shareholders approved Advisory vote on the compensation of named executive officers at the 2026-05-27 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Spyre Therapeutics, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm at the 2026-05-27 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Spyre Therapeutics, Inc. shareholders approved Election of three Class I directors at the 2026-05-27 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
The Company’s stockholders elected three Class I directors, Mark McKenna, Cameron Turtle, and Laurie Stelzer, each to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.